LONDON, Oct 21 (Reuters) - An experimental diabetes drug from AstraZeneca (AZN.L) and Bristol-Myers Squibb (BMY.N) has delivered mixed results in a second late-stage clinical study, by reducing blood sugar levels but also raising infection rates.
LONDON, Oct 21 (Reuters) - An experimental diabetes drug from AstraZeneca (AZN.L) and Bristol-Myers Squibb (BMY.N) has delivered mixed results in a second late-stage clinical study, by reducing blood sugar levels but also raising infection rates.
